Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 587 participants.
Also called NCT06563895
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 587 participants
- Registry
-
NCT06563895
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Japan, Malaysia, Martinique, Mexico, Netherlands, Portugal, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06563895. Randomized; quadruple masking; primary purpose prevention. Start 2025-05-12 (actual); primary completion 2031-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Condition
- Amyloidosis
- Condition
- Amyloid Cardiomyopathy
- Condition
- Transthyretin Amyloidosis
- Condition
- Cardiomyopathies
- Condition
- Heart Diseases
- Condition
- Polyneuropathies
- Intervention (Drug)
- Acoramidis
- Intervention (Drug)
- Placebo oral tablet
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
Record details
- Record id
cardio:ct-nct06563895- Content hash
91c63a0f6092760258a4a5f246182139e6b90d04fe3493985c96c16dfa15fa01